Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on October 15, 2007, covering events that occurred on October 9, 2007. The filing details the Board of Directors' approval of new compensation arrangements for non-employee directors and cash bonuses for key executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on compensation structures and equity grants.
- Board Cash Retainers: $20,000 for all non-employee directors.
- Committee Chair Retainers: $15,000 (Audit), $12,000 (Compensation), $10,000 (Nominating and Governance).
- Committee Member Retainers: $5,000 (Audit), $3,000 (Compensation), $2,500 (Nominating and Governance).
- Meeting Fees: $1,500 for Board meetings and $750 for Committee meetings in excess of six per year.
- Executive Cash Bonuses: $100,000 to CEO David P. Wright; $50,000 each to CFO Christopher C. Camut and VP Eric I. Richman.
Material Changes and Equity Grants
The Board approved the following equity grants under the 2007 Long-Term Incentive Compensation Plan:
- Initial Grant: Options to purchase 20,000 shares of common stock per non-employee director at an exercise price of $5.25 per share (based on the October 9, 2007 closing price on AMEX).
- Vesting Schedule: 50% vests immediately; the remaining 50% vests on the one-year anniversary.
- Future Grants: Options to purchase 10,000 shares per director at future annual meetings, with immediate vesting.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of operational risks. The document is strictly a disclosure of compensatory arrangements approved by the Board.
Key Facts for Investor Verification
- Verify the total number of non-employee directors to calculate the aggregate cash and equity compensation cost.
- Confirm the impact of the $5.25 exercise price relative to the current market price of PharmAthene stock.
- Review the 2007 Long-Term Incentive Compensation Plan to ensure sufficient shares are available for these grants.
- Note that the filing date (October 15, 2007) is six days after the event date (October 9, 2007).